Company news
Arcturus Therapeutics Holdings Inc. news in 2021
Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2021, newest first.
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
December 15, 2021
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
December 12, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 21, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
November 7, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 24, 2021
Arcturus Therapeutics Announces Leadership Appointments
October 20, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
October 11, 2021
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
September 21, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 21, 2021
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
September 7, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
September 6, 2021
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
August 8, 2021
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
August 2, 2021
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
August 1, 2021
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
August 1, 2021
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
July 27, 2021
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
July 25, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
May 9, 2021
Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021
May 2, 2021
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
February 28, 2021
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
February 21, 2021
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021
February 18, 2021
Arcturus Therapeutics to Present at Upcoming Investor Conferences
February 10, 2021
Arcturus Therapeutics to Present at Upcoming Investor Conference
January 5, 2021
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
January 3, 2021
Calls in 2021
- Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q3 2021 Earnings Call
Nov 8, 2021
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q2 2021 Earnings Call
Aug 9, 2021
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2021 Earnings Call
May 10, 2021
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q4 2020 Earnings Call
Mar 1, 2021
Transcript
Decks in 2021
- Investor Presentation (November 2021)
Investor deck · 44 slides · Nov 16, 2021
- Q2 2021 Earnings Presentation
Earnings · 46 slides · Aug 9, 2021
- Investor Presentation (May 2021)
Investor deck · 42 slides · May 10, 2021
- Corporate Update (March 2021)
Corporate update · 42 slides · Mar 1, 2021